{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-174506","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.933695+00:00","generated_at":"2026-05-17T19:43:42.071298+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sana reports $90.1M cash, $40-45M facility impairment; positive UP421 data at 6 months","bullets":["Cash, cash equivalents and marketable securities ~$90.1M as of July 31, 2025.","Expects $40-45M non-cash impairment on Bothell/Seattle facilities due to sublease plans and manufacturing shift.","Raised $29.1M net proceeds via ATM sale of 7.44M shares between April 1 and August 6, 2025.","UP421 trial meets all endpoints: transplanted beta cells survive, produce insulin, evade immune detection at 6 months.","Sonja Schrepfer, SVP and Head of Hypoimmune Platform, resigned to pursue other opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-174506","json":"https://secwatch.observer/filing/0001193125-25-174506.json","markdown":"https://secwatch.observer/filing/0001193125-25-174506.md","text":"https://secwatch.observer/filing/0001193125-25-174506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000119312525174506/0001193125-25-174506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000119312525174506/d36055d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:43:42.071298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}